<DOC>
	<DOCNO>NCT01677780</DOCNO>
	<brief_summary>This open-label , extension study design provide continue treatment RO5045337 participant complete parent study NO21279 ( NCT00623870 ) , NO21280 ( NCT00559533 ) , NP25299 ( NCT01164033 ) , NP28021 ( NCT01605526 ) NP28023 ( NCT01635296 ) . Participants eligible participate study complete required Phase 1 study assessment primary objective respective parent protocol evidence clinical benefit ( defined parent protocol ) . Participants continue similar dose formulation available ( exceed maximum tolerate dose [ MTD ] maximum safely administer dose formulation Phase 1 ) schedule RO5045337 treatment receive time transition parent clinical study protocol .</brief_summary>
	<brief_title>An Extension Study RO5045337 Participants Participating Previous Roche-sponsored Cancer Studies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Participants must meet inclusion criterion outline respective parent protocol : NO21279 ( NCT00623870 ) , NO21280 ( NCT00559533 ) , NP25299 ( NCT01164033 ) , NP28021 ( NCT01605526 ) NP28023 ( NCT01635296 ) Participants must complete one follow clinical study protocol determine clinical benefit treatment conclusion require study analysis define respective parent protocol : NO21279 ( NCT00623870 ) , NO21280 ( NCT00559533 ) , NP25299 ( NCT01164033 ) , NP28021 ( NCT01605526 ) NP28023 ( NCT01635296 ) Participants must meet exclusion criterion outline respective parent protocol : NO21279 ( NCT00623870 ) , NO21280 ( NCT00559533 ) , NP25299 ( NCT01164033 ) , NP28021 ( NCT01605526 ) NP28023 ( NCT01635296 ) Participants develop disease progression/ require antitumor therapy parent protocol Participants stop study drug dose great 56 day Participants continue require dose modification Participants worsen adverse event Participants unrelated adverse event , medical illness , change performance status , per investigator discretion , put high risk continue participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>